Stock MPIT MEDICAL PROGNOSIS INSTITUTE A/S
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Medical Prognosis Institute A/S Nasdaq Copenhagen

Equities

MPIT

DK0060732477

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
AQ
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
AQ
Top Premarket Gainers
MT
Top Premarket Gainers
MT
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split
MT
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
AQ
Transcript : Allarity Therapeutics, Inc. - Shareholder/Analyst Call
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
AQ
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
CI
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
AQ
Allarity Therapeutics : Material Agreement - Form 8-K
PU
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding
CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
AQ
Allarity Therapeutics, Inc. Announces Termination of Marie Foegh as Chief Medical Officer
CI
Allarity Therapeutics to Present at Biomarkers 2024
AQ
Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP
CI
Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board
CI
Allarity Therapeutics, Inc. announced that it expects to receive $0.8 million in funding from 3i, LP
CI
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLR Stock
  4. MPIT Stock
  5. News Medical Prognosis Institute A/S